LAVA Therapeutics NV isa clinical stage immuno-oncology company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LVTX is expected to report earnings to rise 155.77% to -33 cents per share on August 26
Q2'25
Est.
$-0.33
Q1'25
Beat
by $0.19
Q4'24
Beat
by $0.16
Q3'24
Missed
by $0.13
Q2'24
Beat
by $0.02
The last earnings report on May 14 showed earnings per share of -12 cents, beating the estimate of -31 cents. With 14.13K shares outstanding, the current market capitalization sits at 34.20M.